GSK pumps $50m into new-gen neuromodulation techs

Pharmaceuticals group GlaxoSmithKline has launched a new $50m venture capital fund dedicated to investing in “bioelectronic medicines”, an emerging generation of neuromodulation technologies designed to treat diseases ranging from autoimmune and inflammatory conditions to respiratory disorders.